Abstracts tagged "Fc receptors"

Abstract Number: 1955 • 2014 ACR/ARHP Annual Meeting
Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Monoclonal antibodies (mAbs) targeting B cell antigens CD20 and CD22 are used to treat patients with SLE either in the clinic or in clinical…
Abstract Number: 1814 • 2014 ACR/ARHP Annual Meeting
RNA-Containing Immune Complexes Shift Human Neutrophils from Phagocytosing Cells to Efficient Releasers of Oxidized DNA in a Process Requiring Crosstalk Between Toll-like Receptors and Fc Gamma Receptor IIa
Christian Lood¹, Xizhang Sun², Lena Tanaka², Andrew Oberst³, Jeffrey Ledbetter² and Keith B. Elkon², ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Department of Immunology, University of Washington, Seattle, WA
Background/Purpose Neutrophil extracellular traps (NETs), the extrusion of chromatin to capture microbes, has recently emerged as a possible mechanism that may increase the autoantigenic burden…
Abstract Number: 989 • 2014 ACR/ARHP Annual Meeting
Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Incomplete B-cell depletion using rituximab (RTX) is associated with poor clinical response in some individuals with RA and SLE, in particular. However, the precise…
Abstract Number: 178 • 2013 ACR/ARHP Annual Meeting
Fc-Gamma Receptor Genetic Variation In Kawasaki Disease
Carline E. Tacke^1,2, Willemijn B. Breunis^3,4, Long T. Hoang¹, Eileen Png¹, Judy Geissler⁵, Sietse Nagelkerke⁴, Justine Ellis^6,7, Sonia Davila⁸, Chiea Chuen Khor⁸, Michael Levin⁹, David Burgner^10,11, Chisato Shimizu¹², Jane C. Burns¹², Martin L. Hibberd¹ and Taco W. Kuijpers^4,13, ¹Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore, ²Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ³Pediatric rheumatology and immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Blood cell research, Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, ⁵Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, ⁶Murdoch Childrens Research Institute, Parkville, Australia, ⁷Department of Paediatrics, The University of Melbourne, Parkville, Australia, ⁸Human Genetics, Genome Institute of Singapore, Singapore, Singapore, ⁹Department of Pediatrics, Imperial College London, London, United Kingdom, ¹⁰The royal Children's Hospital, Murdoch Childrens Research Institute, Parkville, Australia, ¹¹Department of Paediatrics, The University of Melbourne, Melbourne, Australia, ¹²Pediatrics, UC San Diego, School of Medicine, La Jolla, CA, ¹³Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands
Abstract on behalf of the International Kawasaki Disease Genetics Consortium. Background/Purpose: Kawasaki disease (KD) is a pediatric vasculitis of unknown etiology with a substantial genetic…
Abstract Number: 1143 • 2013 ACR/ARHP Annual Meeting
Increased Frequency Of Pratroling Monocytes In Experimental Arthritis and Rheumatoid Arthritis Patients In Response To IL6-R Blockade
Julie Quentin¹, Jessy Presumey², Florence Apparailly², Yves-Marie Pers³, Pascale Louis Plence⁴ and Christian Jorgensen³, ¹Inserm U844, Montpellier, France, ²U844, Inserm, Montpellier, France, ³Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁴INSERM U844 Montpellier, Montpellier, France
Background/Purpose: Monocytes represent a heterogeneous circulating population of immune cells that play important roles in the inflammatory response. Two main functional subsets of human monocytes…
Abstract Number: 1074 • 2012 ACR/ARHP Annual Meeting
TLR2 Deletion Promotes Arthritis and Joint Destruction Through Reduction of IL-10
Qi Quan Huang¹, Renee E. Koessler¹, Robert Birkett², Harris R. Perlman³, Lianping Xing⁴ and Richard M. Pope⁵, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose: TLR2 signaling pathway has been suggested as a potential therapeutic target in RA. However, studies with mice deficient in TLR2 (TLR2-/-) and IL-1Ra suggest…
Abstract Number: 329 • 2012 ACR/ARHP Annual Meeting
The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen-Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines
Polly Pine¹, Ayodele Apatira¹, Betty Y. Chang¹, Nathan Schoettler², Elliott B. Grossbard³ and Ernest Brahn², ¹Pharmacology, Rigel Pharmaceuticals, So San Francisco, CA, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Rigel Pharmaceuticals, So San Francisco, CA
Background/Purpose: Spleen tyrosine kinase (SYK) is expressed in hematopoietic cells and is a major downstream regulator of signaling through Fcγ and immunoglobulin receptors as well…
Abstract Number: 20 • 2012 ACR/ARHP Annual Meeting
Osteoclastogenesis Is Inhibited by Immune Complexes Through Activating Fcγ Receptors
Lilyanne C. Grevers¹, Peter L.E.M. van Lent², Teun J. de Vries³, Vincent Everts³, J. Sjef Verbeek⁴ and Wim B. van den Berg⁵, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Oral Cell Biology, ACTA, UVA, VU University Amsterdam, Amsterdam, Netherlands, ⁴Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis is characterized by chronic inflammation and osteoclast-mediated bone loss. Co-stimulatory signalling via ITAM- and ITIM-coupled receptors is essential for osteoclast formation and…
Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
Abstract Number: 1056 • 2012 ACR/ARHP Annual Meeting
Fc Receptor Gamma-Dependent Autoimmune Endocarditis in K/BxN Mice
Patricia M. Hobday¹, Jennifer L. Auger², J. Sjef Verbeek³, Jeffrey V. Ravetch⁴ and Bryce A. Binstadt², ¹Department of Pediatrics, Division of Pediatric Rheumatology, University of Minnesota, Minneapolis, MN, ²Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ³Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, ⁴The Rockefeller University, New York, NY
Background/Purpose: Arthritis and endocarditis co-exist in several human rheumatic diseases, including systemic lupus erythematosus, rheumatic fever, and rheumatoid arthritis. K/BxN TCR transgenic mice, well known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].